ADAR1 Capital Management Issues Open Letter to Keros Board
In an important communication, ADAR1 Capital Management, the largest stockholder of Keros Therapeutics (NASDAQ: KROS), has expressed its concerns regarding the Board's handling of critical company matters. Holding approximately 13.3% of the outstanding shares, ADAR1 is advocating for a more constructive dialogue around strategy, capital allocation, and refreshing the Board’s composition.
The Call for Engagement
Months ago, ADAR1 reached out privately to recommend an in-person meeting to discuss strategies that could enhance stockholder value. The expectation was that the feedback from the recent Annual Meeting would encourage the Board to be more receptive to investor dialogues. However, the ongoing reluctance from Keros' management to engage directly with ADAR1 has led to growing frustrations.
ADAR1’s Valuation Insights
ADAR1 believes that Keros is undervalued based on several factors. The firm sees potential in the company’s substantial cash reserves and the projected benefits from its partnership with Takeda regarding elritercept. They suggest that the Board should consider distributing this value directly to stockholders through a Contingent Value Rights (CVR) plan.
Concerns Over Capital Return Plans
Additionally, ADAR1 has raised concerns about the lack of clarity surrounding the company’s previous announcement to return $375 million in excess capital to stockholders. Shareholders have been waiting over two months for more details on this process and timing, and ADAR1 is urging the Board to communicate a definitive plan to implement a special dividend.
Future Steps and Board Dynamics
ADAR1 is hopeful for a cooperative future where both parties can work together to enhance the strategic direction of Keros. If the Board continues to distance itself from their proposed engagements, ADAR1 is prepared to nominate new board members at the next Annual Meeting. They emphasize the need for directors who are willing to acknowledge their fiduciary responsibilities and engage with stockholder perspectives.
The Path to Long-Term Value
ADAR1 firmly believes that Keros stands on the brink of substantial long-term value creation for its investors. However, achieving this goal requires a Board receptive to hearing and working with its stockholders. The call to engage in meaningful dialogue is not just a request but a strategic opportunity for the Keros leadership to align with its investors for mutual benefit.
About ADAR1 Capital Management
ADAR1 Capital Management is an SEC-registered investment manager based in Austin, Texas, specializing in public and private equity investments within the life sciences and biotechnology sectors. Founded by Dr. Daniel Schneeberger in October 2018, the firm has garnered a strong reputation based on its extensive experience, which spans over two decades. With a mix of scientific research and healthcare investing, the team focuses on strategies that resonate with the evolving dynamics of the healthcare industry.
Frequently Asked Questions
What is the purpose of ADAR1's open letter to Keros?
The letter aims to urge Keros' Board to engage on strategic issues, capital allocation, and Board refreshment for better shareholder outcomes.
What does ADAR1 believe regarding Keros' undervaluation?
ADAR1 believes Keros is undervalued based on its cash reserves and potential value from partnerships, suggesting a distribution to stockholders through CVR.
What concerns did ADAR1 raise about capital returns?
ADAR1 is concerned about the lack of updates on Keros' announcement regarding the return of $375 million in excess capital to shareholders.
What actions might ADAR1 take if engagement is refused?
If the Board continues to be unresponsive, ADAR1 may seek to elect new directors who are interested in engaging with stockholders.
Who is behind ADAR1 Capital Management?
Dr. Daniel Schneeberger founded ADAR1, which focuses on life sciences investments and is known for its deep expertise in healthcare and biopharmaceuticals.
